ReviewAnnals of gastroenterology2012
Endocrine and metabolic manifestations in inflammatory bowel disease.
Review in Annals of gastroenterology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04105348 (The Association of Diabetes Mellitus and Inflammatory Bowel Disease), which is not on this map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Association of Diabetes Mellitus and Inflammatory Bowel Disease
Who cites it
23 citing papers in PubMed, 41 citations in OpenAlex.
- Fatigue in inflammatory bowel disease: Mechanisms, assessment, and management strategies.Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association · 2026Article
- Metformin in gastrointestinal cancers and inflammatory bowel disease: Unraveling its mechanisms and therapeutic applications.iScience · 2026Review
- Systemic Consequences of Inflammatory Bowel Disease Beyond Immune-Mediated Manifestations.Journal of clinical medicine · 2025Review
- Gut, bone, and muscle: the triad of osteosarcopenia in inflammatory bowel disease.Intestinal research · 2025Review
- Risk Factors and Awareness of Bone Fragility in Inflammatory Bowel Disease in Taiwan: A Cross-Sectional Study.Biomedicines · 2025Article
- Periodontal disease: A systemic condition.Periodontology 2000 · 2024Review
- Causal effects of inflammatory bowel disease on risk of type 2 diabetes: a two-sample multivariable Mendelian randomization study.Acta diabetologica · 2024Article
- Post-hospitalization Short Versus Long Steroid Taper Strategies in Patients With Acute Severe Ulcerative Colitis: A Comparison of Clinical Outcomes.Crohn's & colitis 360 · 2024Article
- Intestinal flora and linear growth in children.Frontiers in pediatrics · 2023Review
- Oxidative stress, hormones, and effects of natural antioxidants on intestinal inflammation in inflammatory bowel disease.Frontiers in endocrinology · 2023Review
- Alterations in Blood Plasma Metabolome of Patients with Lesniowski-Crohn's Disease Shortly after Surgical Treatment-Pilot Study.Metabolites · 2022Article
- Impact of Inflammatory Bowel Disease (IBD) and IBD Medications on Risk of Hyperlipidemia andFrontiers in medicine · 2022Article
- Sarcopenia and Vitamin D Deficiency in Patients with Crohn's Disease: Pathological Conditions That Should Be Linked Together.Nutrients · 2021Review
- A Vicious Cycle of Osteosarcopeniain Inflammatory Bowel Diseases-Aetiology, Clinical Implications and Therapeutic Perspectives.Nutrients · 2021Review
- Growth, puberty, and bone health in children and adolescents with inflammatory bowel disease.BMC pediatrics · 2021Article
- Serum adropin levels are reduced in patients with inflammatory bowel diseases.Scientific reports · 2020Article
- GI inflammation Increases Sodium-Glucose Cotransporter Sglt1.International journal of molecular sciences · 2019Article
- Increased Risk of Diabetes in Inflammatory Bowel Disease Patients: A Nationwide Population-based Study in Korea.Journal of clinical medicine · 2019Article
- Article
- Genetic and Metabolic Signals during Acute Enteric Bacterial Infection Alter the Microbiota and Drive Progression to Chronic Inflammatory Disease.Cell host & microbe · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Extraintestinal manifestations from nearly every organ system are common in inflammatory bowel disease (IBD). This review article describes the epidemiology, pathogenesis, diagnosis and management of the main endocrine and metabolic manifestations in IBD, including metabolic bone disease, growth retardation, hypogonadism, pubertal delay, lipid abnormalities and insulin resistance. These clinical problems are commonly interrelated and they share a common basis, influenced by disease-related inflammation and nutritional status. In addition to nutritional support, every effort should be made to achieve and maintain disease remission, thus correcting the underlying chronic inflammation. The criteria for screening and diagnosing osteoporosis are described and treatment options are discussed (lifestyle advice, vitamin D and calcium supplementation, use of bisphosphonates or other specific antiosteoporotic agents, correction of hypogonadism). Chronic glucocorticoid therapy may affect growth as well as predispose to osteoporosis. The diagnosis and management of growth failure, pubertal delay and hypogonadism in IBD are discussed.
Indexed as
Identifiers
24714153PMC3959350W2137206429What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.